Source: Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Xiang Tong, Dongguang Wang, Sitong Liu, Yao Ma, Hong Fan. Can YKL-40 be used as a biomarker and therapeutic target for adult asthma?. Eur Respir J, 51 (1) 1702194; 10.1183/13993003.02194-2017

Member's Comments

No comment yet.

Related content which might interest you: The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Is CCL18 a potential biomarker of type-2 asthma? Source: Virtual Congress 2020 – Phenotypes of asthma and COPD Year: 2020 Mast cells in asthma: biomarker and therapeutic target Source: Eur Respir J 2016; 47: 1040-1042 Year: 2016 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 Are T2 biomarkers of any help in diagnosing asthma? Source: Virtual Congress 2020 – New tools for diagnosis of obstructive diseases Year: 2020 YKL-40 protein as a marker of asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010 Serum periostin is not a good biomarker to identify Th2-driven inflammation in COPD Source: International Congress 2018 – Studying novel biomarkers in asthma and COPD Year: 2018 Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021 Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD Source: Eur Respir J 2014; 43: 951-953 Year: 2014 Lipocalin-2: a biomarker potentially associated with predisposition to COPD Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 The role of airways 17ß-estradiol as a biomarker of severity in post-menopausal asthma Source: Virtual Congress 2020 – Respiratory homeostasis and structural changes in disease Year: 2020 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 eNose breathprints as surrogate biomarkers for classifying asthma patients by atopy Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019 Lots of promising targets and biomarkers, but how can we deliver the next generation of severe asthma trials? Source: International Congress 2019 – Beyond T2 mechanisms in asthma: who are the other players? Year: 2019